Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome

References

• March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51.
   PubMed Web of Science ®Google Scholar
• Mumm H, Altinok ML, Henriksen JE, et al. Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndrome. Hum Reprod 2016;31:1105–12.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237–45.
   PubMed Web of Science ®Google Scholar
• Cinar N, Kizilarslanoglu MC, Harmanci A, et al. Depression, anxiety and cardiometabolic risk in polycystic ovary syndrome. Hum Reprod 2011;26:3339–45.
   PubMed Web of Science ®Google Scholar
• Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol 2007;66:373–9.
   PubMed Web of Science ®Google Scholar
• Hahn S, Janssen OE, Tan S, et al. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol 2005;153:853–60.
   PubMed Web of Science ®Google Scholar
• Greenwood EA, Pasch LA, Shinkai K, et al. Putative role for insulin resistance in depression risk in polycystic ovary syndrome. Fertil Steril 2015;104:707–14.e1.
   PubMed Web of Science ®Google Scholar
• Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27:920–4.
   PubMed Web of Science ®Google Scholar
• Dokras A, Sarwer DB, Allison KC, et al. Weight Loss and Lowering Androgens Predict Improvements in Health Related Quality of Life in Women with PCOS. J Clin Endocrinol Metab 2016;101:2966–74.
   PubMed Web of Science ®Google Scholar
• Cinar N, Harmanci A, Demir B, Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod 2012;27: 1840–5.
   PubMed Web of Science ®Google Scholar
• Claman P, Graves GR, Kredentser JV, et al. SOGC clinical practice guidelines. Hirsutism: evaluation and treatment. J Obstet Gynaecol Can 2002;24:62–73.
   PubMedGoogle Scholar
• Skovlund CW, Morch LS, Kessing LV, Lidegaard O. Association of hormonal contraception with depression. JAMA Psychiatry 2016;73:1154–62.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565–92.
   PubMed Web of Science ®Google Scholar
• Hahn S, Benson S, Elsenbruch S, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod 2006;21:1925–34.
   PubMed Web of Science ®Google Scholar
• Huang T, Chen PC, Wu MH, Lin CY. Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. Health Qual Life Outcomes 2016;14:119.
   PubMed Web of Science ®Google Scholar
• Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril 2011;95:1059–66. e1–7.
   PubMed Web of Science ®Google Scholar
• Moll E, van Wely M, Lambalk CB, et al. Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Hum Reprod 2012;27:3273–8.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Altinok ML, Mumm H, et al. Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 2014;99:2584–91.
   PubMed Web of Science ®Google Scholar
• Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002;17:1729–37.
   PubMed Web of Science ®Google Scholar
• Harris-Glocker M, Davidson K, Kochman L, et al. Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. Fertil Steril 2010;93:1016–19.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–63.
   PubMed Web of Science ®Google Scholar
• Nielsen TL, Hagen C, Wraae K, et al. Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. J Clin Endocrinol Metab 2007;92:2696–705.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161–8.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148–56.
   PubMed Web of Science ®Google Scholar
• Ravn P, Haugen AG, Glintborg D. Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol 2013;38:59–76.
   PubMed Web of Science ®Google Scholar
• Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update 2008;14:15–25.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622–9.
   PubMed Web of Science ®Google Scholar
• McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014;67:267–77.
   PubMed Web of Science ®Google Scholar